Innovative Collaboration Between Imugene and JW Therapeutics to Revolutionize Cancer Treatment
Strategic Collaboration to Combat Cancer
Imugene Ltd and JW Therapeutics (Shanghai) Co., LTD have recently joined forces in a strategic collaboration focused on revolutionizing cancer treatment. This partnership aims to evaluate a promising new therapy that combines Imugene's novel oncolytic virus, CF33-CD19 (marketed as onCARlytics), with JW's highly regarded CD19 CAR-T cell therapy, Carteyva®. This collaboration targets refractory solid tumors, which are particularly challenging to treat.
The Approach
The innovative partnership establishes a framework that includes preclinical studies along with a Phase 1 investigator-initiated trial (IIT) to be conducted in China. This critical initiative aims to tackle hard-to-treat cancers by leveraging an avant-garde
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.